HomeMBIO • NASDAQ
add
Mustang Bio Inc
Previous close
$1.17
Day range
$1.01 - $1.15
Year range
$1.01 - $65.00
Market cap
3.60M USD
Avg Volume
708.53K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | -26.00K | -100.29% |
Net income | -952.00K | 88.95% |
Net profit margin | — | — |
Earnings per share | 3.63 | 110.22% |
EBITDA | 77.00K | 100.90% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 6.84M | 9.70% |
Total assets | 9.31M | -47.54% |
Total liabilities | 13.18M | -25.19% |
Total equity | -3.87M | — |
Shares outstanding | 3.30M | — |
Price to book | -0.55 | — |
Return on assets | 0.79% | — |
Return on capital | -1.22% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -952.00K | 88.95% |
Cash from operations | -2.00M | 72.47% |
Cash from investing | — | — |
Cash from financing | 4.94M | 24.77% |
Net change in cash | 2.94M | 188.31% |
Free cash flow | -1.54M | 68.98% |
About
Mustang Bio is an American clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency. Wikipedia
Founded
2015
Headquarters
Website
Employees
6
